<DOC>
	<DOCNO>NCT02130687</DOCNO>
	<brief_summary>In study investigator test hypothesis dipeptidyl peptidase IV ( DPP4 ) inhibition attenuate antihypertensive effect angiotensin-converting enzyme ( ACE ) inhibition angiotensin receptor blockade calcium channel blockade . The investigator hypothesize effect mediate substance P .</brief_summary>
	<brief_title>Effect Chronic ACE DPP4 Inhibition Blood Pressure</brief_title>
	<detailed_description>The use dipeptidyl peptidase IV ( DPP4 ) inhibitor treatment type 2 diabetes ( T2DM ) grow rapidly . The majority patient T2DM also take ACE inhibitor angiotensin receptor blocker ( ARBs ) order reduce cardiovascular renal morbidity mortality . DPP4 ACE inhibitor share common vasoactive substrate substance P. Substance P act vasodilator also activate sympathetic nervous system . Understanding interactive effect DPP4 ACE inhibitor blood pressure neurohumoral activation important implication million patient T2DM take drug concurrently .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Age 18 80 year old For female subject follow condition must meet : Postmenopausal status least 1 year , Statuspost surgical sterilization , If childbearing potential , utilization barrier method birth control willingness undergo urine βHCG test prior drug treatment every study day T2DM , define 1 following time screen visit : Hgb A1C ≥6.5 % , Fasting plasma glucose ≥126mg/dL , 2hour plasma glucose ≥200 mg/dL follow 75gr oral glucose load Hypertension , define : Seated SBP ≥130 mm Hg three occasion document medical record , Seated DBP ≥80 mm Hg three occasion document medical record , Treatment antihypertensive medication minimum 6 month Type 1 diabetes Poorly control T2DM , define Hgb A1C &gt; 8.7 % Use antidiabetic medication metformin least 12 month prior initiation study Secondary hypertension Subjects participate weightreduction program last 6 month whose weight increase decreased 5 kg precede 6 month Pregnancy Breastfeeding Treatment drug primarily metabolize CYP3A4 ( e.g . cisapride , pimozide ) Clinically significant gastrointestinal impairment could interfere drug absorption Cardiovascular disease myocardial infarction within 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy diastolic dysfunction acceptable ) , deep vein thrombosis , pulmonary embolism , second thirddegree AV block , mitral valve stenosis , hypertrophic cardiomyopathy Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 3 x upper limit normal range ) Impaired renal function ( eGFR &lt; 50mL/min/1.73m2 determine MDRD equation ) History presence immunological hematological disorder . History pancreatitis know pancreatic lesion History angioedema take ACE inhibitor Hematocrit &lt; 35 % Treatment anticoagulants Diagnosis asthma require use inhale β2 agonist 1 time per week Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult Treatment systemic glucocorticoid within last 6 month Treatment lithium salt Treatment investigational drug 1 month precede study Mental condition render subject unable understand nature , scope , possible consequence study Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin Converting Enzyme Inhibitors</keyword>
	<keyword>Dipeptidyl Peptidase IV Inhibitors</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Ramipril</keyword>
</DOC>